Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
No adjuvant treatment has been established for patients who remain at high risk for
recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node
metastasis following initial surgery for esophageal squamous cell carcinoma
(ESCC).Controversy still exists regarding the role of adjuvant immunotherapy for ESCC
patients who do not achieve pCR after neoadjuvant chemotherapy plus surgery and clinical T1-2
N0 patients with incidental pathologic lymph node metastasis following initial surgery. To
investigate the outcomes of adjuvant Sintilimab in patients with locally advanced ESCC, we
initiated this randomized controlled trial (RCT).